Poseida Therapeutics (NASDAQ:PSTX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.42) by 40.48 percent. The company reported quarterly sales of $28.14 million which beat the analyst consensus estimate of $11.67 million by 141.22 percent. This is a 172.09 percent increase over sales of $10.34 million the same period last year.
Poseida Therapeutics Q1 2024 Adj EPS $(0.25) Beats $(0.42) Estimate, Sales $28.14M Beat $11.67M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.